ASCO: Spotlight shines on PARP inhibitors, but no star emerges
This article was originally published in Scrip
The side effects of drugs that inhibit poly ADP-ribose polymerase (PARP) are so tolerable and their activity in BRCA-positive tumors is so remarkable that cancer patients are seeking out clinical trials and clinicians are eager to enroll women with breast and ovarian cancer in the studies.
You may also be interested in...
Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors
Tesaro Inc.'s stock price more than doubled on June 29 after the company reported positive progression-free survival (PFS) data for its PARP inhibitor niraparib in the Phase III NOVA clinical trial, which tripled PFS for some women with ovarian cancer compared with placebo – a result that lifted the values of competing firms.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.